268 results on '"Byhardt R"'
Search Results
2. Superiority of combined chemoradiotherapy to radiotherapy alone in patients with esophageal cancers. An intergroup study
3. Radiotherapy Patterns of Care Study in Lung Carcinoma
4. P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: A clinical/laboratory correlative analysis of RTOG-9003
5. Carcinomas of the Oropharynx Treated with Hyperfractionated Radiation Therapy on Radiation Therapy Oncology Group Protocol 8313
6. Radiation Therapy Oncology Group. Research Plan 2002-2006. Tumor Utilization Committee
7. Is Conventional Dose and Fractionation Required to Prophylactically Treat Neck Lymphatics for Head and Neck Cancer Treated with IMRT?
8. Protein Kinase A RI-α Overexpression is Associated with Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy: A Secondary Analysis of RTOG 92-02
9. A Model for Distant Metastasis Incorporating Tissue Biomarkers from Prostate Cancer Patients in Radiation Therapy Oncology Group (RTOG) 92-02
10. “Less is not Always more”: An Economic Analysis of Radiation Therapy Oncology Group 94–10
11. RTOG 0215 Treatment of Erectile Dysfunction (ED) in Patients Treated With Neoadjuvant and Concurrent Androgen Deprivation (AD) and Radiotherapy (RT) for Prostate Cancer (PC)
12. Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation (HRT): Long-term survival results of Radiation Therapy Oncology Group (RTOG) 9801
13. Higher BED is Associated with Improved Local-regional Control and Survival for NSCLC Treated with Chemoradiotherapy: An RTOG Analysis
14. PD-074 Does response rate in the induction chemotherapy predictsurvival for locally advanced non-small cell lung cancer (LANSCLC)?: Secondary analysis of RTOG 8804/8808
15. P-603 Phase I results of RTOG L-0117; a phase i/II dose intensificationstudy using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC
16. O-042 Overall treatment time during concurrent chemoradiotherapy and outcomes: An RTOG secondary analysis
17. O-041 What is the meaning of local-regional control after chemoradiation for locally advanced NSCLC? An RTOG analysis
18. Impact of overall treatment time during concurrent chemoradiotherapy for locally advanced NSCLC: An RTOG secondary analysis
19. Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with Inoperable NSCLC
20. Comorbidity is an independent factor influencing patient selection for combined modality therapy for treatment of stage III non-small cell lung cancer (NSCLC)
21. Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT): results of the radiation therapy oncology group (RTOG) 98–01 study
22. Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92–02
23. Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation therapy oncology group RTOG
24. Radiotherapy (RT) patterns of care study (PCS) in lung carcinoma
25. Microvessel density (mvd)≥60 does not predict for outcome in advanced head and neck squamous cell carcinoma (HNSCC): results of a prospective study from the RTOG 90-03 trial
26. Treatment, patient and tumor characteristics impact quality of life (QOL) in patients with locally advanced head and neck cancer: Report of the radiation therapy oncology group (RTOG) trial 90-03
27. Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? a secondary analysis of RTOG 94-10
28. Concurrent chemoradiation for locally advanced NSCLC in the RTOG experience: effect of overall treatment time
29. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer
30. Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410
31. Effect of advanced age on outcome in Radiation Therapy Oncology Group studies of locally advanced NSCLC (LA-NSCLC)
32. Age dramatically impacts on the quality-adjusted time without symptoms or toxicity (Q-Twist) in locally advanced non-Small cell lung cancer (LA-NSCLC)-a radiation therapy oncology group (RTOG) analysis
33. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410)
34. Androgen Suppression Plus Radiation Versus Radiation Alone for Patients With D1 (pN+) Adenocarcinoma of the Prostate (Results Based on a National Prospective Randomized Trial, RTOG 85-31)
35. Phase III radiation therapy oncology group (RTOG) trial 86-10 od androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate
36. Are patients with supraclavicular node metastases in non-small cell lung cancer (NSCLC) curable with chemoradiotherapy?
37. 238 Response, failure patterns and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC)
38. 244 Toxicity in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC)
39. 247 Phase III study comparing chemotherapy and radiation therapy with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer (NSCLC) with spread to mediastinal lymph nodes (N2): A radiation therapy oncology group study (RTOG 89-01)
40. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
41. Progress Report of Combined Chemoradiotherapy Versus Radiotherapy Alone in Patients With Esophageal Cancer
42. 1007 The need for central pathology tumor grading in prostate cancer using radiation therapy oncology group(RTOG) 8531
43. 120 Response, toxicity, failure patterns and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy (CT) and radiation therapy (RT) for locally advanced non-small cell carcinoma of the lung (NSCLC)
44. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.
45. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
46. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer
47. Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms?
48. Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies
49. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13
50. Comparison of Prognostic Factors and Survival Among Black Patients and White Patients Treated With Irradiation for Non-Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.